SMARCA2 and acute myeloid leukemia: In one study, dual loss of SMARCA2 and SMARCA4 activity either by using allosteric dual inhibitors, such as BRM011 and BRM014, or by knock-down approaches, significantly impaired the viability of a diverse panel of AML cell lines, including those that did not display sensitivity to SMARCA4 knockdown [88].